ClinicalTrials.gov

Key Record Dates

ClinicalTrials.gov Identifier: NCT00464646
Brief Title: Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

First Submitted : April 19, 2007
First Submitted that Met QC Criteria : April 19, 2007
First Posted : April 23, 2007 (Estimate)

Results First Submitted : August 24, 2012
Results First Submitted that Met QC Criteria : August 24, 2012
Results First Posted : September 26, 2012 (Estimate)

Last Update Submitted that Met QC Criteria : July 17, 2014
Last Update Posted : July 25, 2014 (Estimate)